Advertisement

Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma

Published:September 24, 2022DOI:https://doi.org/10.1016/j.clgc.2022.09.009

      Abstract

      Introduction

      Metastatic non clear cell renal cell carcinoma (nccRCC) is an heterogenous group, usually excluded from phase 3 trials. We report real life data of prognosis and systemic management of those patients.

      Methods

      We retrospectively included 102 metastatic nccRCC patients (unspecified papillary, n = 10; type 1 and 2 papillary n = 10 and n = 32; translocation RCC, n = 9; chromophobe, n = 14; collecting duct, n = 14) treated between 2006 and 2020. Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated.

      Results

      Among patients who underwent pathological review, 40.8% presented a complete histological discordance. First line treatments were mainly tyrosine kinase inhibitor (60.8%), combination including immunotherapy (7.8%) or combination of chemotherapy (13.7%). Median ORR ranged from 0% in unspecified papillary RCC to 42.9% in type 1 papillary RCC. Median PFS ranged from 2.9 months in collecting duct carcinoma to 10.9 months in type 1 papillary RCC. Median OS ranged from 6.8 months in collecting duct carcinoma to 29.1 months in MiT family translocation RCC. Thirty (29.4%) patients were included in a treatment trial during their treatment course.

      Conclusion

      Metastatic nccRCC patients have variable prognosis due to heterogeneity of histological subtypes. Their diagnosis and access to therapeutic innovation remain suboptimal. Dedicated prospective trials are needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Capitanio U
        • Bensalah K
        • Bex A
        • et al.
        Epidemiology of renal cell carcinoma [figure presented].
        Eur Urol [Internet]. 2019; 75: 74-84https://doi.org/10.1016/j.eururo.2018.08.036
        • Leibovich BC
        • Lohse CM
        • Crispen PL
        • et al.
        Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.
        J Urol [Internet]. 2010; 183: 1309-1316https://doi.org/10.1016/j.juro.2009.12.035
        • Kattan MW
        • Reuter V
        • Motzer RJ
        • Katz J
        • Russo P.
        A postoperative prognostic nomogram for renal cell carcinoma.
        J Urol. 2001; 166: 63-67
        • Kroeger N
        • Xie W
        • Lee JL
        • et al.
        Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria.
        Cancer. 2013; 119: 2999-3006
        • Rini BI
        • Plimack ER
        • Stus V
        • et al.
        Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2019; 380: 1116-1127
        • Motzer RJ
        • Tannir NM
        • McDermott DF
        • et al.
        Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma.
        N Engl J Med. 2018; 378: 1277-1290
        • Choueiri TK
        • Powles T
        • Burotto M
        • et al.
        Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.
        N Engl J Med. 2021; 384: 829-841
        • Powles T.
        Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 1.
        Ann Oncol. 2021; 32: 422-423
        • Armstrong AJ
        • Halabi S
        • Eisen T
        • et al.
        Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial.
        Lancet Oncol [Internet]. 2016; 17 (Available from:): 378-388https://doi.org/10.1016/S1470-2045(15)00515-X
        • Tannir NM
        • Jonasch E
        • Albiges L
        • et al.
        Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (espn): a randomized multicenter phase 2 trial.
        Eur Urol [Internet]. 2016; 69: 866-874https://doi.org/10.1016/j.eururo.2015.10.049
      1. Evans AE, Angio GJD, Sather HN. Median Follow-Up in Clinical Trials. 2019;191–2.

        • Moch H
        • Cubilla AL
        • Humphrey PA
        • Reuter VE
        • Ulbright TM.
        The 2016 WHO classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours.
        Eur Urol [Internet]. 2016; 70: 93-105https://doi.org/10.1016/j.eururo.2016.02.029
        • Motzer RJ
        • Bacik J
        • Mariani T
        • Russo P
        • Mazumdar M
        • Reuter V.
        Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
        J Clin Oncol. 2002; 20: 2376-2381
        • Knox JJ
        • Barrios CH
        • Kim TM
        • et al.
        Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
        Ann Oncol. 2017; 28: 1339-1345
        • Escudier B
        • Porta C
        • Schmidinger M
        • et al.
        Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019; 30: 706-720
        • McDermott DF
        • Lee JL
        • Ziobro M
        • et al.
        Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non–clear cell renal cell carcinoma.
        J Clin Oncol. 2021; 39: 1029-1039
        • Koshkin VS
        • Barata PC
        • Zhang T
        • et al.
        Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
        J Immunother Cancer. 2018; 6: 1-7
        • Chahoud J
        • Msaouel P
        • Campbell MT
        • et al.
        Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis.
        Oncologist. 2020; 25: 252-258
        • Tykodi SS
        • Gordan LN
        • Alter RS
        • et al.
        Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
        J Clin Oncol. 2021; 39: 309
        • Graham J
        • Wells JC
        • Dudani S
        • et al.
        Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
        Eur J Cancer. 2022; 171: 124-132
        • Papanikolaou D
        • Ioannidou P
        • Koukourikis P
        • et al.
        Systemic therapy for chromophobe renal cell carcinoma: a systematic review.
        Urol Oncol. 2020; 38: 137-149https://doi.org/10.1016/j.urolonc.2019.11.006
        • Lee CH
        • Voss MH
        • Carlo MI
        • et al.
        Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates.
        J Clin Oncol. 2022; 40: 2333-2341
        • Ray-coquard I
        • Montesco MC
        • Coindre JM
        • et al.
        Sarcoma: Concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.
        Ann Oncol [Internet]. 2012; 23 (Available from:): 2442-2449https://doi.org/10.1093/annonc/mdr610
      2. Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia [Internet]. Vol. 34, Modern Pathology. Springer US; 2021. 1392–1424 p. Available from: 10.1038/s41379-021-00779-w

      3. Carlo MI, Khan N, Zehir A, Patil S, Ged Y, Redzematovic A. Original report abstract comprehensive genomic analysis of metastatic non – clear-cell renal cell carcinoma to identify therapeutic targets. 2020;1–18.

        • Barthélémy P
        • Rioux-Leclercq N
        • Thibault C
        • et al.
        Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data.
        Cancer Treat Rev. 2021; 97
        • Pal SK
        • Tangen C
        • Thompson IM
        • et al.
        A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
        Lancet [Internet]. 2021; 397 (Available from): 695-703https://doi.org/10.1016/S0140-6736(21)00152-5
        • Chen YB
        • Xu J
        • Skanderup AJ
        • et al.
        Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
        Nat Commun [Internet]. 2016; 7: 1-10https://doi.org/10.1038/ncomms13131
        • Pal SK
        • Choueiri TK
        • Wang K
        • et al.
        Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling.
        Eur Urol [Internet]. 2016; 70: 516-521https://doi.org/10.1016/j.eururo.2015.06.019
        • Srinivasan R
        • Gurram S
        • Harthy M
        • et al.
        Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
        J Clin Oncol. 2020; 38: 5004
        • Webster BR
        • Rompre-Brodeur A
        • Daneshvar M
        • Pahwa R
        • Srinivasan R.
        Kidney cancer: from genes to therapy.
        Curr Probl Cancer [Internet]. 2021; 45 (Available from:)100773https://doi.org/10.1016/j.currproblcancer.2021.100773
        • Heng DYC
        • Xie W
        • Regan MM
        • et al.
        Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
        J Clin Oncol. 2009; 27: 5794-5799
        • Jung KS
        • Lee SJ
        • Park SH
        • et al.
        Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study.
        Cancer Res Treat. 2018; 50: 488-494
        • Lee CH
        • Li C
        • Perini RF
        • Hoehn D
        • Albiges L.
        KEYNOTE-B61: open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).
        J Clin Oncol. 2021; 39: TPS4595
        • Dudani S
        • de Velasco G
        • Wells JC
        • et al.
        Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival.
        JAMA Netw Open. 2021; 4: 1-11
        • Negrier S
        • Rioux-Leclercq N
        • Ferlay C
        • et al.
        Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
        Eur J Cancer. 2020; 129: 107-116
        • Ravaud A
        • Oudard S
        • de Fromont M
        • et al.
        First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: A phase II study (SUPAP) by the French Genitourinary Group (GETUG).
        Ann Oncol. 2015; 26: 1123-1128
        • Escudier B
        • Molinie V
        • Bracarda S
        • et al.
        Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
        Eur J Cancer. 2016; 69: 226-235
        • Choueiri TK
        • Heng DYC
        • Lee JL
        • et al.
        Efficacy of savolitinib vs sunitinib in patients with MET -driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial.
        JAMA Oncol. 2020; 6: 1247-1255
        • McGregor BA
        • McKay RR
        • Braun DA
        • et al.
        Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features.
        J Clin Oncol. 2020; 38: 63-70